Business
Why the Mesoblast (ASX:MSB) share price is sinking 11% lower
The Mesoblast limited (ASX: MSB) share price has come under pressure on Tuesday after the release of an announcement.
At the time of writing the allogeneic cellular medicines developer’s shares are down 11% to $4.03.
What did Mesoblast announce?
This morning Mesoblast announced the top-line results from the landmark DREAM-HF Phase 3 randomised controlled trial of its allogeneic cell therapy rexlemestrocel-L (REVASCOR) in 537 patients with advanced chronic heart failure.
According to the release, after a 30-month follow-up, patients with advanced chronic heart failure who received a single endomyocardial treatment with rexlemestrocel-L on top of maximal therapies had a 60% reduction in the incidence of heart attacks or strokes and…
-
Noosa News23 hours agoWoman dead and man rushed to hospital with gunshot wound following crash near Aussie World on Queensland’s Sunshine Coast
-
General22 hours agoSummah Richards, 12, mourned after fatal e-scooter in Laidley, Queensland
-
Noosa News23 hours agoMan arrested after police chase: Driver shot, woman dies in crash
-
General23 hours agoBoy’s drowning adds to ‘most horrific’ Easter toll